Entering text into the input field will update the search result below

Aeglea BioTherapeutics GAAP EPS of -$1.00 beats by $0.02, revenue of $18.73M beats by $1.33M

Mar. 08, 2022 7:23 AM ETSpyre Therapeutics, Inc. (SYRE)By: Deepa Sarvaiya, SA News Editor
  • Aeglea BioTherapeutics press release (NASDAQ:AGLE): FY GAAP EPS of -$1.00 beats by $0.02.
  • Revenue of $18.73M beats by $1.33M.
  • As of December 31, 2021, the company had available cash, cash equivalents, marketable securities and restricted cash of $95.0 million

Recommended For You


Have a tip? Submit confidentially to our News team. Found a factual error? Report here.

About SYRE

SymbolLast Price% Chg
Market Cap
Yield (TTM)
Rev Growth (YoY)
Short Interest
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
Spyre Therapeutics, Inc.
Biomea Fusion, Inc.
Avidity Biosciences, Inc.
4D Molecular Therapeutics, Inc.
Vera Therapeutics, Inc.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.